SHL Telemedicine Ltd. (SHLT) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

SHL Telemedicine Ltd. (SHLT) Healthcare & Pipeline Overview

SHL Telemedicine Ltd. provides remote cardiac monitoring solutions and telemedicine services, leveraging its proprietary devices and monitoring centers. The company operates in a competitive healthcare information services market, focusing on early heart attack detection and chronic disease management through technology-driven solutions in Israel, Europe, and internationally.

What Is the Investment Thesis for SHLT?

SHL Telemedicine operates in the growing telemedicine market, driven by increasing demand for remote patient monitoring and chronic disease management. The company's focus on cardiac care, particularly its SmartHeart device, positions it to capitalize on the need for early heart attack detection. However, SHL Telemedicine's negative P/E ratio of -1.20 and a profit margin of -49.5% indicate profitability challenges. The company's collaborations with Mayo Clinic and the Hebrew University of Jerusalem represent potential catalysts for innovation and market expansion. Investors should closely monitor SHL Telemedicine's ability to improve its financial performance and scale its operations in a competitive landscape.

Based on FMP financials and quantitative analysis

SHLT Key Highlights

• Market capitalization of $33.6M, indicating a small-cap company.
• Negative P/E ratio of -1.20, reflecting current losses.
• Gross margin of 45.4%, suggesting potential for profitability if operating expenses are managed effectively.
• Beta of 0.29, indicating lower volatility compared to the overall market.
• No dividend yield, as the company does not currently distribute dividends.

Who Are SHLT's Competitors?

SHLT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SHLT's Key Strengths?

• Proprietary telemedicine technology and devices.
• Established presence in Israel and Europe.
• Collaborations with Mayo Clinic and the Hebrew University of Jerusalem.
• Experienced management team.

What Are SHLT's Weaknesses?

• Negative profitability and high operating expenses.
• Small market capitalization.
• Limited geographic reach compared to larger competitors.
• Reliance on a few key products and services.

What Could Drive SHLT Stock Higher?

• Results from the Mayo Clinic collaboration evaluating SmartHeart's impact on post-heart attack outcomes are expected in Q4 2026.
• Expansion of telemedicine services into new geographic markets.
• Development and launch of new telemedicine devices for chronic disease management.
• Publication of research on the AI tool for predicting cardiac events developed with the Hebrew University of Jerusalem and the Hadassah Medical Center in Q2 2027.

What Are the Key Risks for SHLT?

• Financial-distress signal — its Altman Z-Score of -1.45 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-49.8%) — the business is not currently generating profit on shareholder capital.
• Competition from larger telemedicine companies with greater resources.
• Regulatory changes and reimbursement challenges affecting telemedicine services.
• Technological obsolescence of existing telemedicine devices.
• Negative profitability and high operating expenses.
• Currency fluctuations affecting the value of the ADR.

What Are the Growth Opportunities for SHLT?

• Expansion into New Geographic Markets: SHL Telemedicine has the opportunity to expand its services into new geographic markets beyond Israel and Europe. The global telemedicine market is projected to reach $460 billion by 2030, offering significant growth potential. Entering new markets would require regulatory approvals and strategic partnerships, but could significantly increase SHL's revenue base. Timeline: 2-3 years.
• Strategic Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and health insurance companies can drive adoption of SHL Telemedicine's solutions. These partnerships can provide access to a larger patient base and integrate SHL's technology into existing healthcare workflows. The market for healthcare partnerships is estimated to be worth $100 billion annually. Timeline: Ongoing.
• Development of New Telemedicine Devices: Investing in research and development to create new telemedicine devices can expand SHL Telemedicine's product portfolio and address unmet needs in remote patient monitoring. Focus areas could include devices for monitoring other chronic conditions such as diabetes or respiratory diseases. The market for remote patient monitoring devices is expected to reach $30 billion by 2028. Timeline: 3-5 years.
• Leveraging Artificial Intelligence for Predictive Analytics: SHL Telemedicine's collaboration with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an AI tool for predicting cardiac events presents a significant growth opportunity. AI-powered predictive analytics can improve patient outcomes and reduce healthcare costs. The market for AI in healthcare is projected to reach $45 billion by 2026. Timeline: 1-2 years.
• Increased Adoption of Remote Cardiac Monitoring: With the rising prevalence of heart disease, there is a growing need for remote cardiac monitoring solutions. SHL Telemedicine's SmartHeart device and monitoring services are well-positioned to address this need. The global cardiac monitoring market is expected to reach $25 billion by 2027. Timeline: Ongoing.

What Opportunities Does SHLT Have?

• Expansion into new geographic markets.
• Development of new telemedicine devices and services.
• Increased adoption of remote patient monitoring.
• Leveraging artificial intelligence for predictive analytics.

What Threats Does SHLT Face?

• Competition from larger telemedicine companies.
• Regulatory changes and reimbursement challenges.
• Technological obsolescence.
• Economic downturns affecting healthcare spending.

What Are SHLT's Competitive Advantages?

• Proprietary telemedicine devices and monitoring technology.
• Established telemedicine centers with trained healthcare professionals.
• Collaborations with leading medical institutions.
• Experience in the telemedicine market since 1987.

What Does SHLT Do?

Founded in 1987 and headquartered in Tel Aviv, Israel, SHL Telemedicine Ltd. has evolved into a provider of personal telemedicine solutions. The company's core business revolves around developing and marketing devices and services that enable remote patient monitoring, primarily focused on cardiac health. SHL Telemedicine offers a range of products, including the SmartHeart mobile 12-lead ECG device for detecting heart attacks, CardioSen'C, Cardio'B, and Cardio Beeper 12/12 for transmitting ECG data. Additionally, they provide devices for monitoring weight (TeleWeight), blood pressure (TelePress), lung function (TeleBreather), and blood oxygen saturation (TelePulse Oximeter). These devices transmit data to SHL's telemedicine centers, where healthcare professionals can analyze the information and provide timely interventions. SHL Telemedicine serves a diverse clientele, including individual patients, health insurance companies, hospitals, clinics, and physicians. The company has also established collaborations with Mayo Clinic and the Hebrew University of Jerusalem to enhance its capabilities in cardiac event prediction and management using artificial intelligence.

What Products and Services Does SHLT Offer?

• Develop and market personal telemedicine solutions.
• Offer mobile 12-lead ECG devices for heart attack detection.
• Provide remote monitoring services through telemedicine centers.
• Offer devices for monitoring weight, blood pressure, lung function, and blood oxygen saturation.
• Serve patients, health insurance companies, hospitals, clinics, and physicians.
• Collaborate with medical institutions to develop AI-powered diagnostic tools.

How Does SHLT Make Money?

• Subscription-based service model for remote monitoring.
• Sales of telemedicine devices to individuals and healthcare providers.
• Partnerships with health insurance companies for patient monitoring programs.
• Data analysis and reporting services for healthcare providers.

What Industry Does SHLT Operate In?

SHL Telemedicine operates within the healthcare information services industry, which is experiencing growth due to the increasing adoption of telemedicine and remote patient monitoring. The market is competitive, with companies like Akili Interactive Labs (AKLI), Back Health (BACK), Grace Therapeutics Holdings (GRCE), IRadimed Corp (IRD), and Lianyungang Port (LIANY) also vying for market share. The industry is driven by factors such as an aging population, the rising prevalence of chronic diseases, and advancements in technology. SHL Telemedicine's focus on cardiac care differentiates it within this broader landscape.

Who Are SHLT's Key Customers?

• Individual patients requiring remote cardiac monitoring.
• Health insurance companies seeking to improve patient outcomes and reduce costs.
• Hospitals and clinics looking to expand their telemedicine capabilities.
• Physicians who want to remotely monitor their patients' health.

ROE -50%Key Financial Metrics

Return on equity for SHL Telemedicine Ltd. stands at -49.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -34.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -12.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -83.6%, the inverse of the P/E and a quick read on earnings relative to price.

How SHL Telemedicine Ltd. Is Valued

SHL Telemedicine Ltd. carries a market capitalization of $33.6M, placing it in the micro-cap category. Relative to its peer group, SHLT's quantitative score of 43/100 is below the peer average of 59/100.

F-Score 4/9Financial Health

SHL Telemedicine Ltd.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.45 places it in the distress zone, a signal of elevated financial risk.

SHLT Financials

SHLT Latest News

No recent news available for SHLT.

SHLT Analyst Consensus

SHLT MoonshotScore

What Investors Ask About SHL Telemedicine Ltd. (SHLT) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources